List of Contents

Assisted Reproductive Technology Market Size, Share, and Trends 2024 to 2034

Assisted Reproductive Technology Market (By Product: Instrument, Accessory & Disposable, Reagents & media; By Technology: In-Vitro Fertilization, Artificial Insemination; By Diagnosis: Ovulation Testing, Hysterosalpingography; By End-User: Ambulatory surgical centers, Hospitals, Clinics, Diagnostic centers, Gynecology Centers, Feminist Health Centers, IVF Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

  • Last Updated : July 2023
  • Report Code : 2329
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Assisted Reproductive Technology Market 

5.1. COVID-19 Landscape: Assisted Reproductive Technology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Assisted Reproductive Technology Market, By Product

8.1. Assisted Reproductive Technology Market, by Product, 2023-2032

8.1.1. Instrument

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Accessory & Disposable

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Reagents & media

8.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Assisted Reproductive Technology Market, By Technology

9.1. Assisted Reproductive Technology Market, by Technology, 2023-2032

9.1.1. In-Vitro Fertilization (IVF)

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Artificial Insemination

9.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Assisted Reproductive Technology Market, By Diagnosis 

10.1. Assisted Reproductive Technology Market, by Diagnosis, 2023-2032

10.1.1. Ovulation Testing

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Hysterosalpingography

10.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Assisted Reproductive Technology Market, By End-User 

11.1. Assisted Reproductive Technology Market, by End-User, 2023-2032

11.1.1. Ambulatory surgical centers

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. Hospitals

11.1.2.1. Market Revenue and Forecast (2021-2032)

11.1.3. Clinics

11.1.3.1. Market Revenue and Forecast (2021-2032)

11.1.4. Diagnostic centers

11.1.4.1. Market Revenue and Forecast (2021-2032)

11.1.5. Gynecology Centers

11.1.5.1. Market Revenue and Forecast (2021-2032)

11.1.6. Feminist Health Centers

11.1.6.1. Market Revenue and Forecast (2021-2032)

11.1.7. IVF Centers

11.1.7.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Assisted Reproductive Technology Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2021-2032)

12.1.2. Market Revenue and Forecast, by Technology (2021-2032)

12.1.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.1.4. Market Revenue and Forecast, by End-User (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2021-2032)

12.1.5.2. Market Revenue and Forecast, by Technology (2021-2032)

12.1.5.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2021-2032)

12.1.6.2. Market Revenue and Forecast, by Technology (2021-2032)

12.1.6.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2021-2032)

12.2.2. Market Revenue and Forecast, by Technology (2021-2032)

12.2.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.2.4. Market Revenue and Forecast, by End-User (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2021-2032)

12.2.5.2. Market Revenue and Forecast, by Technology (2021-2032)

12.2.5.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2021-2032)

12.2.6.2. Market Revenue and Forecast, by Technology (2021-2032)

12.2.6.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2021-2032)

12.2.7.2. Market Revenue and Forecast, by Technology (2021-2032)

12.2.7.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2021-2032)

12.2.8.2. Market Revenue and Forecast, by Technology (2021-2032)

12.2.8.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2021-2032)

12.3.2. Market Revenue and Forecast, by Technology (2021-2032)

12.3.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.3.4. Market Revenue and Forecast, by End-User (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2021-2032)

12.3.5.2. Market Revenue and Forecast, by Technology (2021-2032)

12.3.5.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2021-2032)

12.3.6.2. Market Revenue and Forecast, by Technology (2021-2032)

12.3.6.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2021-2032)

12.3.7.2. Market Revenue and Forecast, by Technology (2021-2032)

12.3.7.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2021-2032)

12.3.8.2. Market Revenue and Forecast, by Technology (2021-2032)

12.3.8.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2021-2032)

12.4.2. Market Revenue and Forecast, by Technology (2021-2032)

12.4.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.4.4. Market Revenue and Forecast, by End-User (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2021-2032)

12.4.5.2. Market Revenue and Forecast, by Technology (2021-2032)

12.4.5.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2021-2032)

12.4.6.2. Market Revenue and Forecast, by Technology (2021-2032)

12.4.6.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2021-2032)

12.4.7.2. Market Revenue and Forecast, by Technology (2021-2032)

12.4.7.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2021-2032)

12.4.8.2. Market Revenue and Forecast, by Technology (2021-2032)

12.4.8.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2021-2032)

12.5.2. Market Revenue and Forecast, by Technology (2021-2032)

12.5.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.5.4. Market Revenue and Forecast, by End-User (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2021-2032)

12.5.5.2. Market Revenue and Forecast, by Technology (2021-2032)

12.5.5.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2021-2032)

12.5.6.2. Market Revenue and Forecast, by Technology (2021-2032)

12.5.6.3. Market Revenue and Forecast, by Diagnosis (2021-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2021-2032)

Chapter 13. Company Profiles

13.1. Vitrolife AB

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. The Cooper Companies, Inc (Cooper Surgical Inc.)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Progyny Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Oxford Gene Technology

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Millendo Therapeutics, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck KGaA (EMD Serono, Inc)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Genera Biomedx

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Fujifilm Holdings Corporation (Irvine Scientific Sales Company)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Cook Medical Inc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client